Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $62.76
    -1.75 (-2.71%)

    Market Cap: $9.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TG Therapeutics Inc (TGTX) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    TG Therapeutics (TGTX) is expected to report earnings on Jan 11, 2027. In the quarter ended Sep 30, 2026, TG Therapeutics reported EPS of $0.35, above the $0.28 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    28%(11/40)
    Avg Surprise
    -1.04%
    Streak
    1 Q

    Upcoming Estimates

    Reports Jan 11, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.56
    Range$0.32 - $0.72
    10 analysts
    Revenue Consensus
    $294.51M
    Range$261.56M - $315.00M
    10 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.60
    Range$0.60 - $0.60
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.45+33.3%
    60d ago$0.45+33.3%
    30d ago$0.45+33.3%
    7d ago$0.45+33.3%
    Current$0.60
    Revenue Consensus
    $298.03M
    Range$283.00M - $314.40M
    3 analysts

    Next Report

    TGTX has an expected report date of Jan 11, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 300.0% above the $0.14 reported for the quarter ended Dec 31, 2025.

    TGTX Earnings Call

    The latest TGTX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, TGTX beat 11, missed 27 and matched 2. The widest gap in the table came in the quarter ended Sep 30, 2023, when EPS landed 630.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.35$0.28$0.19 - $0.35+25.00%Beat+118.7%40 up, 2 downNov 9, 2026N/A
    Jun 30, 2026$0.05$0.41$0.31 - $0.61-87.80%Miss-70.6%55 up, 0 downAug 3, 2026$240.34M
    Mar 31, 2026$0.18$0.28$0.12 - $0.46-35.71%Miss+500.0%41 up, 0 downMay 6, 2026$204.92M
    Dec 31, 2025$0.14$0.35$0.27 - $0.41-60.00%Miss-6.7%53 up, 0 downFeb 26, 2026$192.57M
    Sep 30, 2025$0.16$0.22$0.11 - $0.33-27.27%Miss+700.0%60 up, 1 downNov 3, 2025$161.71M
    Jun 30, 2025$0.17$0.29$0.16 - $0.61-41.38%Miss+325.0%51 up, 0 downAug 4, 2025$141.15M
    Mar 31, 2025$0.03$0.17$0.12 - $0.23-82.35%MissN/A50 up, 1 downMay 5, 2025$120.86M
    Dec 31, 2024$0.15$0.09$0.06 - $0.57+66.67%BeatN/A50 up, 0 downMar 3, 2025$108.19M
    Sep 30, 2024$0.02$0.03-$0.05 - $0.08-33.33%Miss-97.3%80 up, 0 downNov 4, 2024$83.88M
    Jun 30, 2024$0.04-$0.04-$0.09 - -$0.02+200.00%BeatN/A70 up, 0 downAug 6, 2024$73.47M
    Mar 31, 2024-$0.07-$0.04-$0.12 - $0.05-75.00%MissN/A70 up, 0 downMay 1, 2024$63.47M
    Dec 31, 2023-$0.10-$0.10-$0.17 - -$0.040.00%In lineN/A71 up, 0 downFeb 28, 2024$43.97M
    Sep 30, 2023$0.73$0.10-$0.28 - $0.62+630.00%BeatN/A70 up, 1 downNov 1, 2023$165.81M
    Jun 30, 2023-$0.34-$0.25-$0.31 - -$0.20-36.00%MissN/A81 up, 0 downAug 1, 2023$16.07M
    Mar 31, 2023-$0.28-$0.34-$0.50 - -$0.31+17.65%BeatN/A71 up, 0 downMay 1, 2023$7.80M
    Dec 31, 2022-$0.39-$0.26-$0.34 - -$0.13-50.00%MissN/A81 up, 0 downFeb 28, 2023$81000
    Sep 30, 2022-$0.26-$0.38-$0.47 - -$0.19+31.58%BeatN/A70 up, 0 downNov 10, 2022$94000
    Jun 30, 2022-$0.30-$0.57-$0.74 - -$0.37+47.37%BeatN/A70 up, 0 downAug 8, 2022$594000
    Mar 31, 2022-$0.51-$0.59-$0.80 - -$0.45+13.56%BeatN/A73 up, 0 downMay 10, 2022$2.02M
    Dec 31, 2021-$0.70-$0.68-$0.77 - -$0.45-2.94%MissN/A7N/AMar 1, 2022$2.32M
    Sep 30, 2021-$0.65-$0.57-$0.61 - -$0.48-14.04%MissN/A7N/ANov 4, 2021$2.03M
    Jun 30, 2021-$0.59-$0.50-$0.56 - -$0.46-18.00%MissN/A6N/AAug 2, 2021$1.54M
    Mar 31, 2021-$0.69-$0.49-$0.65 - -$0.35-40.82%MissN/A6N/AMay 10, 2021$793000
    Dec 31, 2020-$0.72-$0.61-$0.72 - -$0.43-18.03%MissN/A6N/AMar 2, 2021$38000
    Sep 30, 2020-$0.73-$0.44-$0.48 - -$0.32-65.91%MissN/A6N/ANov 9, 2020$38000
    Jun 30, 2020-$0.47-$0.33-$0.41 - -$0.27-42.42%MissN/A5N/AAug 10, 2020$38000
    Mar 31, 2020-$0.48-$0.37-$0.49 - -$0.27-29.73%MissN/A4N/AMay 11, 2020$38000
    Dec 31, 2019-$0.44-$0.46-$0.65 - -$0.29+4.35%BeatN/A5N/AMar 3, 2020$38000
    Sep 30, 2019-$0.69-$0.35-$0.37 - -$0.28-97.14%MissN/A4N/ANov 12, 2019$38000
    Jun 30, 2019-$0.42-$0.42-$0.48 - -$0.300.00%In lineN/A6N/AAug 9, 2019$38000
    Mar 31, 2019-$0.43-$0.44-$0.49 - -$0.32+2.27%BeatN/A6N/AMay 10, 2019$38000
    Dec 31, 2018-$0.69-$0.44-$0.49 - -$0.41-56.82%MissN/A5N/AMar 1, 2019$38000
    Sep 30, 2018-$0.43-$0.50-$0.58 - -$0.48+14.00%BeatN/A6N/ANov 9, 2018$38000
    Jun 30, 2018-$0.59-$0.50-$0.58 - -$0.41-18.00%MissN/A6N/AAug 7, 2018$38000
    Mar 31, 2018-$0.59-$0.42-$0.48 - -$0.34-40.48%MissN/A6N/AMay 8, 2018$38000
    Dec 31, 2017-$0.46-$0.44-$0.49 - -$0.32-4.55%MissN/A6N/AMar 8, 2018$38000
    Sep 30, 2017-$0.48-$0.40-$0.51 - -$0.29-20.00%MissN/A4N/ANov 8, 2017$38000
    Jun 30, 2017-$0.45-$0.38-$0.52 - -$0.32-18.42%MissN/A4N/AAug 9, 2017$38000
    Mar 31, 2017-$0.52-$0.36N/A-44.44%MissN/AN/AN/AMay 5, 2017$38000
    Dec 31, 2016-$0.48-$0.36N/A-33.33%MissN/AN/AN/AMar 10, 2017$37714
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 257.1% from the year before. It was -$1.59 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.50+257.1%
    Dec 31, 2024$0.14+1300.0%
    Dec 31, 2023$0.01N/A
    Dec 31, 2022-$1.46N/A
    Dec 31, 2021-$2.63N/A
    Dec 31, 2020-$2.40N/A
    Dec 31, 2019-$1.98N/A
    Dec 31, 2018-$2.30N/A
    Dec 31, 2017-$1.91N/A
    Dec 31, 2016-$1.59N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,76012
    2026Q2Jun 30, 20266,73312
    2026Q1Mar 31, 20264,83313
    2025Q4Dec 31, 20254,81612
    2025Q3Sep 30, 20254,45113
    2025Q2Jun 30, 20253,61311
    2025Q1Mar 31, 20254,23111
    2024Q4Dec 31, 20245,65410

    2026Q3 Earnings Call

    Opening remarks

    Jenna Bosco Chief Communications Officer Thank you. Welcome, everyone, and thank you for joining us this morning. I'm Jenna Bosco, and with me to discuss TG Therapeutics' Third Quarter 2026 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Hari Miskin, our Chief Development Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer. Following our safe harbor statement, Mike will begin with an overview of our recent corporate developments. Hari will then discuss highlights from our recent data presentation, followed by Adam, who will provide an update on our commercial efforts. Sean will conclude our prepared remarks with a review of our financial results before we open the call for Q&A. Before we begin, I'd like to remind everyone that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may include expectations regarding our future operating and financial performance, including sales trends, revenue guidance, projected milestones, development plans, and the outlook for our marketed products and our pipeline products. Please note that these statements are subject to risks and uncertainties that can cause our actual results to differ materially from those indicated. These risks are detailed in our SEC filings. Additionally, any forward-looking statements made today reflect our views only as of this date, and we disclaim any obligation to update or revise them. As a reminder, this conference call is being recorded and will be available for replay for the next 30 days on our website at www.tgtherapeutics.com. With that, I'll now turn the call over to Mike Weiss, our CEO.

    Michael Weiss Chairman and Chief Executive Officer Thank you, Jenna, and good morning, everyone. We appreciate you joining us today. I'm pleased to report another strong quarter for TG with meaningful progress across both our commercial business and development programs. Global revenue for the quarter was approximately $260 million, including $233 million in U.S. BRIUMVI net revenue. With solid third quarter performance and trends pointing to a strong fourth quarter, we're raising our full year global revenue guidance to $1 billion for 2026, a pretty remarkable accomplishment less than four years after launching BRIUMVI. I'd like to pause here to congratulate our team for their hard work and dedication to the MS community and to TG. And as they know, we're just getting started. $1 billion in annual revenue is an important milestone, but I don't believe it comes close to defining the opportunity ahead of us. On our last call, I described BRIUMVI as a starting line for TG, providing the commercial capabilities, financial resources, and scientific foundation to build a value creation engine.

    Frequently Asked Questions About TGTX

    When is TG Therapeutics's next earnings date?

    TG Therapeutics's next earnings report is expected for Jan 11, 2027.

    Did TGTX beat earnings estimates last quarter?

    Yes. TG Therapeutics reported EPS of $0.35 for the quarter ended Sep 30, 2026, above the $0.28 estimate, a 25.00% surprise.

    What EPS do analysts expect from TGTX next quarter?

    The consensus EPS estimate for TG Therapeutics for the quarter ending Dec 31, 2026 is $0.56 from 10 analysts, with estimates from $0.32 to $0.72.

    How often does TGTX beat earnings estimates?

    TG Therapeutics beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -30.36%.